Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
A Phase 2, Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
Commercial Sponsor
Array BioPharma
Summary
Eligible participants will be randomised to receive oral encorafenib and binimetinib in 28-day cycles across two different dosing regimens. In the standard-treatment arm, participants will receive 450 mg encorafenib orally once a day (QD) and 45 mg binimetinib orally twice a day (BID); in the high-dose treatment arm, participants will receive 300 mg encorafenib orally twice a day (BID) and 45 mg binimetinib orally twice a day (BID).